NASDAQ:RARE - Ultragenyx Pharmaceutical Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $53.27 +1.98 (+3.86 %) (As of 11/19/2018 08:06 AM ET)Previous Close$51.29Today's Range$50.79 - $54.355052-Week Range$41.67 - $90.98Volume516,369 shsAverage Volume631,455 shsMarket Capitalization$2.69 billionP/E Ratio-7.10Dividend YieldN/ABeta2.34 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.20 Wall Street analysts have issued ratings and price targets for Ultragenyx Pharmaceutical in the last 12 months. Their average twelve-month price target is $75.3889, suggesting that the stock has a possible upside of 41.52%. The high price target for RARE is $95.00 and the low price target for RARE is $54.00. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyBuyConsensus Rating Score: 2.752.792.792.80Ratings Breakdown: 0 Sell Rating(s)5 Hold Rating(s)15 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)4 Hold Rating(s)15 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)4 Hold Rating(s)15 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)4 Hold Rating(s)16 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $75.3889$85.50$79.00$70.0556Price Target Upside: 41.52% upside15.28% upside1.15% upside17.23% upsideUltragenyx Pharmaceutical (NASDAQ:RARE) Consensus Price Target History Ultragenyx Pharmaceutical (NASDAQ:RARE) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails11/15/2018Credit Suisse GroupSet Price TargetHold$59.00High11/14/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium11/8/2018CitigroupUpgradeSell ➝ Neutral$46.00 ➝ $54.00N/A11/7/2018Canaccord GenuityLower Price TargetBuy$90.00 ➝ $75.00Low11/6/2018Raymond JamesBoost Price TargetOutperform ➝ Buy$53.00 ➝ $57.00Medium10/29/2018WedbushLower Price TargetOutperform ➝ Outperform$90.00 ➝ $88.00High10/29/2018Morgan StanleySet Price TargetHold$92.00 ➝ $70.00High10/29/2018SunTrust BanksLower Price TargetBuy ➝ Buy$83.00 ➝ $54.00Medium10/26/2018Piper Jaffray CompaniesLower Price TargetOverweight$70.00High9/11/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$72.00 ➝ $94.00Low9/2/2018JMP SecuritiesReiterated RatingBuy$94.00Medium8/3/2018Robert W. BairdReiterated RatingBuy$95.00High8/3/2018BarclaysReiterated RatingOverweight ➝ Overweight$74.00 ➝ $92.00High7/17/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$68.00 ➝ $95.00Low6/21/2018creditDowngradeOutperform ➝ Neutral$67.00 ➝ $80.00Medium5/10/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$63.00Medium4/18/2018CowenReiterated RatingBuyMedium4/18/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$74.00 ➝ $77.00High1/22/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh12/4/2017Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $72.00High8/8/2017HC WainwrightReiterated RatingNeutral ➝ Neutral$72.00 ➝ $75.00Low7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00High(Data available from 11/19/2016 forward) This page was last updated on 11/19/2018 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?